Market Overview

RBC Sees Weak Merck Data As Positive For Gilead

Share:

In a note from RBC Capital analyst Michael Yee, Merck & Co., Inc.'s (NYSE: MRK) weaker-than-expected data for hepatitis C is a net positive for Gilead Sciences, Inc. (NASDAQ: GILD).

Merck had looked to shorten hepatitis C treatment by adding Gilead's Sovaldi to its own oral two-drug combination, but the effectiveness came up short, with a high rate of relapses, according to interim data from the study.

In the study, 38.7 percent were cured in four weeks and 86.7 percent were cured in six weeks, according to data presented Monday at the American Association for the Study of Liver Diseases conference in Boston. Those numbers are well below current cure rates exceeding 90 percent, and far below the cure rates approaching 99 percent from Gilead's Sovaldi and Harvoni combination, which should provide a boost for Gilead.

Shares of Merck were lower by 2.2 percent in pre-market trading at $57.83, while Gilead was higher by 2.7 percent at $109.30.

Latest Ratings for MRK

DateFirmActionFromTo
Nov 2019MaintainsOverweight
Oct 2019ReinstatesNeutral
Aug 2019Initiates Coverage OnOutperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Michael Yee RBC CapitalAnalyst Color News Health Care Analyst Ratings General

 

Related Articles (GILD + MRK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NEWCitiUpgrades
BKNGConsumer Edge ResearchInitiates Coverage On2,250.0
EXPEConsumer Edge ResearchInitiates Coverage On100.0
TRIPConsumer Edge ResearchInitiates Coverage On26.0
IAreteInitiates Coverage On39.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Morgan Stanley Downgrades Performant Financial

Brean Capital Positive On Activision Blizzard, Sees Return To Growth